Zymeworks Signs Global Licensing and Collaboration Deal With Roche for ZW209

Bitget2026/10/23 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zymeworks entered an exclusive global licensing collaboration with Roche for DLL3-targeting cancer therapy ZW209, subject to antitrust clearance.
Payments include $55 million upfront, $40 million upon Phase 1b initiation and up to $718 million in additional milestones.
Tiered royalties range from high single digits to mid-teens on global net sales, with patent protection extending into the 2040s.
Roche will fund the Zymeworks-led Phase 1a monotherapy trial and take responsibility for subsequent global development and commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230600OMX_____CNEWS_EN_GNW9851721_en) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zymeworks Signs Global Licensing and Collaboration Deal With Roche for ZW209

You may also like

Crypto prices